After two complete response letters, the FDA granted accelerated approval to Replimune’s oncolytic immunotherapy Tudriqev (vusolimogene oderparepvec-wtpg) plus Opdivo for adults with unresectable advanced cutaneous melanoma progressing after prior PD-1 therapy. The decision leans on the single-arm Phase I/II IGNYTE study: among 91 efficacy-evaluable patients, the combo posted a 24.2% objective response rate and a 14.1-month median duration of response.

Why It Matters To Oncology

• Tudriqev is an intratumoral oncolytic immunotherapy entering a high-unmet-need setting: PD-1–refractory unresectable advanced cutaneous melanoma.

• The approval is notable because FDA reviewers had repeatedly questioned whether IGNYTE, a single-arm trial, provided substantial evidence of effectiveness.

• Clinically, the label creates a new option to pair local viral immunotherapy with nivolumab in patients whose disease has already progressed on anti–PD-1 treatment.

The Financials

• This is a major regulatory win for Replimune after two prior rejections, sharply improving the commercial outlook for its lead asset.

• Accelerated approval means revenue opportunity can begin before confirmatory evidence is complete, though long-term value still depends on successful verification of benefit.

• Bristol Myers Squibb also stands to benefit indirectly through expanded use of Opdivo in this combination setting.

What They're Saying

• FDA staff argued as recently as last week that design and tumor-response assessment issues in IGNYTE may have inflated efficacy and obscured Tudriqev’s contribution versus Opdivo alone.

• But an advisory committee voted 10-3 that the data were evaluable and clinically meaningful given the unmet need and the biologic rationale for combining oncolytic virus therapy with PD-1 blockade.

• Primary investigator Michael Wong said the approval provides “a potent oncolytic immunotherapy” for a broad melanoma population, including BRAF-naïve, pretreated, and adjuvant-relapsed patients.

What's Next

• Replimune must confirm clinical benefit in the 400-patient IGNYTE-3 trial of Tudriqev plus Opdivo.

• According to ClinicalTrials.gov, IGNYTE-3 is expected to read out in 2030.

• For clinicians, the near-term watch points are uptake in PD-1–refractory melanoma, durability in real-world use, and whether confirmatory data resolve lingering questions about the magnitude of Tudriqev’s added effect.